AbbVie (NYSE:ABBV) had its price objective increased by Piper Jaffray Companies from $115.00 to $130.00 in a research report sent to investors on Friday, January 26th. Piper Jaffray Companies currently has an outperform rating on the stock.
A number of other research firms also recently commented on ABBV. Evercore ISI restated an outperform rating and set a $100.00 price target (up from $95.00) on shares of AbbVie in a research report on Saturday, September 30th. Societe Generale lifted their price objective on shares of AbbVie in a research note on Tuesday, November 21st. BMO Capital Markets set a $84.00 price objective on shares of AbbVie and gave the stock a hold rating in a research note on Thursday, January 11th. Jefferies Group lifted their price objective on shares of AbbVie from $115.00 to $120.00 and gave the stock a buy rating in a research note on Thursday, January 4th. Finally, Barclays reaffirmed a hold rating and issued a $68.00 price objective on shares of AbbVie in a research note on Thursday, September 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $117.26.
AbbVie (ABBV) opened at $111.93 on Friday. AbbVie has a fifty-two week low of $60.15 and a fifty-two week high of $125.86. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. The firm has a market cap of $177,682.66, a price-to-earnings ratio of 34.02, a price-to-earnings-growth ratio of 1.06 and a beta of 1.60.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 26th. The company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.04. The firm had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. AbbVie’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period last year, the firm posted $1.20 EPS. sell-side analysts predict that AbbVie will post 7.46 earnings per share for the current year.
In other AbbVie news, insider Laura J. Schumacher sold 145,510 shares of AbbVie stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $96.71, for a total value of $14,072,272.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 450,743 shares of company stock worth $43,153,684. 0.23% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Savant Capital LLC lifted its stake in shares of AbbVie by 1.3% in the second quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock worth $4,433,000 after buying an additional 793 shares during the last quarter. Princeton Capital Management Inc. acquired a new stake in shares of AbbVie in the second quarter worth $1,394,000. Palisade Asset Management LLC lifted its stake in shares of AbbVie by 17.9% in the second quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after buying an additional 10,381 shares during the last quarter. Beaton Management Co. Inc. acquired a new stake in shares of AbbVie in the second quarter worth $528,000. Finally, Greatmark Investment Partners Inc. raised its stake in AbbVie by 3.7% during the 2nd quarter. Greatmark Investment Partners Inc. now owns 35,178 shares of the company’s stock valued at $2,551,000 after purchasing an additional 1,242 shares during the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/piper-jaffray-companies-boosts-abbvie-abbv-price-target-to-130-00.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.